Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT07182643
Starting soon Observational

Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate/Severe Endometriosis Patients

NCT07182643 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Stockholm
Phase
Observational
Started
2025-10-01
Last updated
2025-09-19

Condition(s) studied

Endometriosis

Investigational drug(s) / intervention(s)

Endometrial fluidEndometrial biopsyFollicular fluid

Endometrial fluid: Endometrial fluid collection in the day of OPU

Endometrial biopsy: Endometrial biopsy on the OPU day, Pipelle

Follicular fluid: Follicular fluid sampling on the OPU day

Study summary

This study aims to explore biomarkers in the endometrial fluid and tissue of women with moderate to severe endometriosis, with a specific focus on those involved in pre-receptive endometrium and embryo implantation. This research has the potential to uncover diagnostic indicators of impaired pre-receptive endometrium, examine pathophysiological pathways, and identify future targets for therapeutic intervention. Ultimately, the findings may contribute to more personalized fertility treatments, offering new hope for women struggling with endometriosis-related infertility.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18-40 years old * Diagnosed with moderate/severe endometriosis by ultrasound or laparoscopy (patient group) * Regular menstrual cycles 28-35 days * Speak English or Swedish and agree to participate in the study Exclusion Criteria: * Pregnancy or lactation in the last 3 months * Uterine anomalies * Pelvic inflammatory disease, endometritis, STD * Gynaecological cancers or other malignancies in the patient's history * Smoking (more than 10 cigarettes per day) or alcohol abuse * Immunosuppressing medicines * Major abdominal or pelvic surgery in the last 3 months * A specific genetic disease that is diagnosed before PGT in women undergoing treatment

Primary outcome measure(s)

  • Relative expression levels (e.g., fold change, normalized intensity, or concentration in pg/mL/ng/mL depending on biomarker assay) — 2 years
    Evaluation of the expression levels of selected biomarkers in endometrial fluid samples from patients with moderate to severe endometriosis compared to healthy controls.
  • Percentage of blastoids successfully implanted in vitro (% implantation rate) — 2 years
    Evaluation of the implantation efficiency of blastoids in vitro (endometrial organoids) under controlled laboratory conditions.

Trial sites (1)

FacilityCityRegionStatus
Karolinska Institute and Karolinska University Hospital Huddinge Stockholm Sweden

More Region Stockholm trials in Sweden

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy Starting soon
Metacognitive Therapy for Depression and Generalized Anxiety Disorder in Primary Care, Blended Version of Mediated Treatment Enrolling by invitation
ROTEM in Sepsis Trauma Outcome in Intensive Care Recruiting
Intimate Partner Violence Among People Who Inject Drugs - Prevalence, Risk Factors and Experiences Recruiting
A Comparison of Group Cognitive Behavioural Therapy (CBT) and Structured Activity Group for Adults With Attention Deficit Hyperactivity Disorder (ADHD) Recruiting

Other trials for the same condition

Internet-based ACT for Endometriosis and Chronic Pain Recruiting
Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO) Recruiting
Endoexpedition - Use of a Serious Game to Deliver Patient Information and Decision Aid for Individuals With Endometriosis. Starting soon
First Line Surgery or First Line Fertility Treatment Using Assisted Reproductive Technologies in Patients With Advanced Endometriosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07182643 on ClinicalTrials.gov ↗ ← All trials in Sweden